Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

849 - Selective killing of circulating tumor cells prevents metastasis and extends survival


24 Nov 2018


Poster display - Cocktail


Translational Research

Tumour Site


Yi Rang Kim


Annals of Oncology (2018) 29 (suppl_9): ix23-ix27. 10.1093/annonc/mdy430


Y.R. Kim1, J.W. Choi2

Author affiliations

  • 1 Hemato-oncology, Yuseong Sun Hospital, 34084 - Daejeon/KR
  • 2 Department Of Pharmacology, Kyung Hee University, Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 849


Distant metastasis is initiated by circulating tumor cells (CTCs), which are considered to be a determining factor for the degree of metastasis and the survival of cancer patients. Although CTC-based diagnostic approaches are being rapidly developed, limited studies have proven the benefits of CTC elimination, with most studies providing only hypothetical inference because of unpredictable nature and dynamics of CTCs.


We modified photodynamic therapy to specifically eliminate green fluorescent protein (GFP)-expressing CTCs and evaluated the therapeutic efficacy of CTC elimination via in vitro and in vivo experiments.


When circulating blood is illuminated with a blue laser (λ = 473 nm), the combination of GFP and photosensitizers induces a selective elimination of GFP-expressing CTCs, with limited effect on normal cells. In GFP-expressing cancer cell-infused mice model, numbers of circulating tumor cells were significantly reduced after blue laser illumination. In GFP-expressing cancer cell transplanted mice models, the treatment suppressed distant metastasis and extended the survival of the tumor-bearing mice.


This study using novel photodynamic modality is the first experimental study to demonstrate that selective killing of CTCs delays distant metastasis significantly and ultimately improves survival. In addition, this study directly suggests CTCs are a core seed to be metastasized into secondary organs.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kyung Hee University.


National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA17C0039) Kyung Hee University (KHU-20170844).


Y.R. Kim: CEO: Oncocross. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.